Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

355

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

March 31, 2000

Study Completion Date

April 30, 2002

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

interleukin 2

low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles

BIOLOGICAL

rhuMAb

90 min IV infusion day 7 of each cycle

Trial Locations (34)

10021

Memorial Sloan-Kettering Cancer Center, New York

New York Presbyterian Hospital - Cornell Campus, New York

10029

Mount Sinai Medical Center, NY, New York

11030

CCOP - North Shore University Hospital, Manhasset

North Shore University Hospital, Manhasset

13210

CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse

State University of New York - Upstate Medical University, Syracuse

19111

Fox Chase Cancer Center, Philadelphia

19899

CCOP - Christiana Care Health Services, Wilmington

21201

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

27710

Duke Comprehensive Cancer Center, Durham

33140

CCOP - Mount Sinai Medical Center, Miami Beach

38163

University of Tennessee, Memphis Cancer Center, Memphis

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

52242

University of Iowa Hospitals and Clinics, Iowa City

60612

University of Illinois at Chicago Health Sciences Center, Chicago

60637

University of Chicago Cancer Research Center, Chicago

63110

Barnes-Jewish Hospital, St Louis

65203

Ellis Fischel Cancer Center - Columbia, Columbia

89106

CCOP - Southern Nevada Cancer Research Foundation, Las Vegas

92093-0658

University of California San Diego Cancer Center, La Jolla

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20307-5000

Walter Reed Army Medical Center, Washington D.C.

02115

Dana-Farber Cancer Institute, Boston

01655

University of Massachusetts Memorial Medical Center, Worcester

68198-3330

University of Nebraska Medical Center, Omaha

03756

Norris Cotton Cancer Center, Lebanon

14263-0001

Roswell Park Cancer Institute, Buffalo

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

27104-4241

CCOP - Southeast Cancer Control Consortium, Winston-Salem

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

02903

Rhode Island Hospital, Providence

29425-0721

Medical University of South Carolina, Charleston

05401-3498

Vermont Cancer Center, Burlington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00002994 - Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter